Publikationen, an denen er mitarbeitet María D. Odero (15)

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2014

  1. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

    Journal of Hematology and Oncology, Vol. 7, Núm. 1

2012

  1. Epigenetic regulation of miRNA genes in acute leukemia

    Leukemia, Vol. 26, Núm. 3, pp. 395-403

  2. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics

    PLoS ONE, Vol. 7, Núm. 8

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

2005

  1. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas

    Genes Chromosomes and Cancer, Vol. 43, Núm. 4, pp. 414-423

  2. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 22-26

  3. Erratum: NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2 (Cancer Genetics and Cytogenetics (2005) 157 (151-6))

    Cancer Genetics and Cytogenetics

  4. NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2

    Cancer Genetics and Cytogenetics, Vol. 157, Núm. 2, pp. 151-156

  5. p53 Aberrations do not predict individual to response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV

    British Journal of Haematology, Vol. 129, Núm. 1, pp. 53-59

2004

  1. Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2 [4]

    Leukemia

  2. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells

    Oncogene, Vol. 23, Núm. 1, pp. 311-316

  3. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements

    Genes Chromosomes and Cancer, Vol. 40, Núm. 3, pp. 179-189

2003

  1. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response

    Haematologica, Vol. 88, Núm. 12, pp. 1425-1426

  2. NUP98 is fused to Adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)

    Cancer Research, Vol. 63, Núm. 12, pp. 3079-3083